Article Text

Download PDFPDF
Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Reply from authors

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors All authors equally contributed to writing the letter.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests GGK has received honoraria for speaking or consultancy from Abbvie, Janssen, Pfizer and Takeda. He has received research support from Janssen, Abbvie, GlaxoSmith Kline, Merck and Shire. He shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE AND PBC. UTI Limited Partnership, assignee. Patent 62/555,397. 7 September 2017.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Patient consent for publication Not required.

Linked Articles